SANES

10.662

-0.43%↓

BBVA

19.435

-0.87%↓

BNP

93.66

+0.01%↑

CABK

11.52

-0.04%↓

INGA

26.005

-1.12%↓

SANES

10.662

-0.43%↓

BBVA

19.435

-0.87%↓

BNP

93.66

+0.01%↑

CABK

11.52

-0.04%↓

INGA

26.005

-1.12%↓

SANES

10.662

-0.43%↓

BBVA

19.435

-0.87%↓

BNP

93.66

+0.01%↑

CABK

11.52

-0.04%↓

INGA

26.005

-1.12%↓

SANES

10.662

-0.43%↓

BBVA

19.435

-0.87%↓

BNP

93.66

+0.01%↑

CABK

11.52

-0.04%↓

INGA

26.005

-1.12%↓

SANES

10.662

-0.43%↓

BBVA

19.435

-0.87%↓

BNP

93.66

+0.01%↑

CABK

11.52

-0.04%↓

INGA

26.005

-1.12%↓

Home・Aandelen Lijst・Sartorius Stedim Biotech.

Sartorius Stedim Biotech.

Gesloten

SectorFinanciën

179.2 -2.08

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

179.1

Max

180.6

Belangrijke statistieken
By Trading Economics
Inkomsten	41M 88M
Verkoop	-11M 762M
K/W Sectorgemiddelde	64.546 41.721
EPS	1.17
Winstmarge	11.569
Werknemers	10,456
EBITDA	26M 225M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+30.03% upside

Dividenden
By Dow Jones
Volgende Winsten	23 jul 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-897M 17B
Vorige openingsprijs	181.28
Vorige sluitingsprijs	179.2

Nieuwssentiment

By Acuity

20%

80%

32 / 439 Rangschikking in Finance

Sartorius Stedim Biotech. Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 jun 2026, 19:20 UTC

Belangrijke Marktbewegers

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

6 jun 2026, 08:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

6 jun 2026, 08:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

6 jun 2026, 04:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

6 jun 2026, 00:14 UTC

Acquisities, Fusies, Overnames

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

5 jun 2026, 21:27 UTC

Winsten

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 jun 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

5 jun 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

5 jun 2026, 20:20 UTC

Acquisities, Fusies, Overnames

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 jun 2026, 20:19 UTC

Acquisities, Fusies, Overnames

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 jun 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

5 jun 2026, 19:26 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

5 jun 2026, 19:26 UTC

Marktinformatie

Hog Futures Tumble to Close Week -- Market Talk

5 jun 2026, 19:10 UTC

Marktinformatie

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 jun 2026, 19:03 UTC

Marktinformatie

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 jun 2026, 18:59 UTC

Marktinformatie

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 jun 2026, 18:47 UTC

Marktinformatie

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 jun 2026, 18:34 UTC

Marktinformatie

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 jun 2026, 18:33 UTC

Acquisities, Fusies, Overnames

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 jun 2026, 17:50 UTC

Winsten

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 jun 2026, 17:27 UTC

Marktinformatie

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 jun 2026, 16:48 UTC

Acquisities, Fusies, Overnames

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 jun 2026, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

5 jun 2026, 16:20 UTC

Marktinformatie

Financial Services Roundup: Market Talk

5 jun 2026, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

5 jun 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

5 jun 2026, 15:44 UTC

Acquisities, Fusies, Overnames

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 jun 2026, 15:26 UTC

Marktinformatie

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 jun 2026, 15:25 UTC

Winsten

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 jun 2026, 15:16 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Sartorius Stedim Biotech. Prognose

Koersdoel

By TipRanks

30.03% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 232.63 EUR 30.03%

Hoogste 262 EUR

Laagste 210 EUR

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Sartorius Stedim Biotech. - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Sartorius Stedim Biotech. - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

32 / 439 Rangschikking in Financiën

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Sartorius Stedim Biotech.

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.